Evidence map›Paper›PMID 34974350›Full record

Trial reportDiagnostic microbiology and infectious disease2022

Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19.

Karen B Jacobson, Natasha Purington, Julie Parsonnet, Jason Andrews, Vidhya Balasubramanian, Hector Bonilla, Karlie Edwards, Manisha Desai, Upinder Singh, Haley Hedlin and 1 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diagnostic microbiology and infectious disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. TNF-αCell reports. Medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Karen B JacobsonDepartment of Medicine, Stanford University, Stanford, CA, USA. Electronic address: kjacobs@stanford.edu.
Natasha PuringtonQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Julie ParsonnetDepartment of Medicine, Stanford University, Stanford, CA, USA.
Jason AndrewsDepartment of Medicine, Stanford University, Stanford, CA, USA.
Vidhya BalasubramanianQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Hector BonillaDepartment of Medicine, Stanford University, Stanford, CA, USA.
Karlie EdwardsDepartment of Medicine, Stanford University, Stanford, CA, USA.
Manisha DesaiQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Upinder SinghDepartment of Medicine, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
Haley HedlinQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Prasanna JagannathanDepartment of Medicine, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA. Electronic address: prasj@stanford.edu.
Stanford University · USStanford Medicine · US

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Computational models of naturally acquired immunity to falciparum malariaU01AI150741 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J, GREENHOUSE, BRYAN R · 2020 to 2024
$7.4M
Global Epidemiology of Infectious DiseasesT32AI052073 · NIAID · STANFORD UNIVERSITY · PI Angelle Desiree LaBeaud, Stephen Patrick Luby · 2003 to 2026
$4.2M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Translational Studies of Plasmodium Falciparum Infection DynamicsK23AI076614 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENHOUSE, BRYAN R · 2008 to 2012
$609k
NCATS NIH HHS UL1 TR003142NIAID NIH HHS K23 AI076614NIAID NIH HHS K24 AI144048NIAID NIH HHS T32 AI052073NIAID NIH HHS U01 AI150741
6 · The paper itself

Abstract

Although the vast majority of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections are uncomplicated, our understanding of predictors of symptom resolution and viral shedding cessation remains limited. We characterized symptom trajectories and oropharyngeal viral shedding among 120 outpatients with uncomplicated Coronavirus Disease of 2019 (COVID-19) enrolled in a clinical trial of Peginterferon Lambda, which demonstrated no clinical or virologic benefit compared with placebo. In the combined trial cohort, objective fever was uncommon, inflammatory symptoms (myalgias, fatigue) peaked at 4 to 5 days postsymptom onset, and cough peaked at 9 days. The median time to symptom resolution from earliest symptom onset was 17 days (95% confidence interval 14-18). SARS-CoV-2 IgG seropositivity at enrollment was associated with hastened resolution of viral shedding (hazard ratio 1.80, 95% confidence interval 1.05-3.1, P = 0.03), but not with symptom resolution. Inflammatory symptoms were associated with a significantly greater odds of oropharyngeal SARS-CoV-2 RNA detection; respiratory symptoms were not. These findings have important implications for COVID-19 screening approaches and trial design.

Indexed as

COVID-19HumansOutpatientsRNA, ViralSARS-CoV-2Virus SheddingRNA, ViralCOVID-19SARS-CoV-2symptom clusteringsymptom progressionviral shedding

Identifiers

PMID34974350
PMCPMC8627385
OpenAlexW3215874796

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.